$PODD · INSULET CORP
Insulet filed its 10-Q for the quarter ended September 30, 2026. Total revenue grew 19.2% YoY to $842.0M (from $706.3M), with gross margin of 75.1% and operating margin of 22.5%. Net income was $141.1M ($2.03 diluted EPS) versus $87.6M ($1.24) a year earlier. Nine-month revenue reached $2,405.4M with net income of $327.1M. The company also disclosed two voluntary medical device recalls (MDCs) related to cannula tears, with a $37.0M liability accrued, and a new $1B buyback authorized in October 2026.
- Q3 revenue $842.0M, up 19.2% YoY from $706.3M.
- Diluted EPS $2.03 vs $1.24 a year ago.
- Gross margin 75.1%; operating margin 22.5%.
- Two voluntary MDCs (cannula tears) accrued $37.0M liability.
- October 2026: $1B buyback authorized through Dec 2028.
Extended-hours last trade $167.00, +1.20% vs regular close of $165.02; regular session rose +6.56% on the day. The strong earnings and buyback news are being received positively.
Insulet delivered accelerating double-digit growth, margin expansion, and a $1B buyback, reinforcing its position as a high-growth medtech compounder.
Insulet's Omnipod insulin delivery franchise continues to outgrow the broader diabetes device market, with international revenue up 31.7% YoY to $266.2M.
Two voluntary medical device recalls related to cannula tears in Omnipod products resulted in a $37.0M accrued liability; warranty reserve adjustments could recur if replacement rates shift.